Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
3SBio Inc. (TRSBF)
Shenyang, CN
3SBio Inc. is a China-based investment holding company deeply engaged in the biopharmaceutical sector, encompassing the entire value chain from research and development to manufacturing, marketing, and sales of its innovative products. The company's extensive biopharmaceutical portfolio caters to a wide array of therapeutic needs. This includes treatments for various blood disorders like TPIAO (for chemotherapy-induced or immune thrombocytopenia), EPIAO and SEPO (recombinant erythropoietins for anemia), and SPARIN (a low-molecular-weight heparin for deep vein thrombosis prophylaxis and treatment, as well as for preventing clotting during hemodialysis), alongside Aiyishu for iron-deficiency anemia. Its autoimmune and inflammatory disease offerings feature YISAIPU, a tumor necrosis factor inhibitor effective against rheumatoid arthritis, ankylosing spondylitis, and psoriasis. In the oncology domain, 3SBio provides Cipterbin for HER2-positive metastatic breast cancer (in combination with chemotherapy), Intefen (a recombinant human interferon for lymphatic/hematopoietic malignancies and viral infections), and Inleusin (human interleukin-2 for renal cell carcinoma, melanoma, and thoracic fluid accumulation). Other specialized products address conditions such as male alopecia and alopecia areata (Mandi), acute rejection post-renal transplant (Xenopax), glycemic control in type 2 diabetes (Byetta), and diabetic retinopathy (Qiming Keli). In addition to its pharmaceutical operations, 3SBio diversifies its activities through services encompassing trading, project management, consulting, technology, and agriculture. The company has forged strategic collaboration agreements with a multitude of international partners, including prominent names like AstraZeneca, Lilly, Toray Industries Inc, Samsung Bioepis, Refuge Biotechnologies, Verseau, TLC, Numab, GenSight, Sensorion, and the Dana-Farber Cancer Institute. Established in 1993, the company maintains its headquarters in Shenyang, China.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | -9.89% | -2.67% | -34.62% | -28.37% | -5.56% | +218.75% | +157.58% | +5.37% | +5.37% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
-
Revenue growth Biotechnology: +1.6%+89.3% ★ Q4'25: +225.4% (vs Q4'23)
-
EPS growth Biotechnology: +29.7%+295.3% ★ Q4'25: +1,147.8% (vs Q4'23)
-
FCF margin FCF growth · Biotechnology: +16.2%+48.7% ★ Q4'25: +64.2% (vs Q4'23)
-
EBIT margin Biotechnology: +0.0%+59.7% ★ Q4'25: +69.7% (vs Q4'23)
-
ROIC Biotechnology: -16.1%+65.2% ★ Q4'25: +231.4% (vs Q4'23)
-
Share dilution Biotechnology: -3.4%0.0% ★ Q4'25: +1.2% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.24× ★ Q4'25: 0.07× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 12 Rev. Ana. 1 EPS Ana. |
Dec 2027 13 Rev. Ana. 1 EPS Ana. |
Dec 2028 8 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
1.67B
est: 1.66B (+0.5%)
|
2.80B
est: 2.86B (-2.3%)
|
3.73B
est: 3.90B (-4.2%)
|
4.58B
est: 4.47B (+2.5%)
|
5.32B
est: 5.44B (-2.3%)
|
5.59B
est: 5.61B (-0.3%)
|
6.38B
est: 6.47B (-1.4%)
|
6.86B
est: 6.72B (+2.0%)
|
7.82B
est: 7.73B (+1.1%)
|
9.11B
est: 8.94B (+1.9%)
|
17.24B
est: 18.37B (-6.2%)
|
10.57B
9.26B – 11.65B
-42.5% YoY
|
11.19B
9.09B – 13.93B
+5.8% YoY
|
12.11B
10.20B – 14.24B
+8.2% YoY
|
| EBITDA |
680.64M
est: 580.26M (+17.3%)
|
981.09M
est: 998.31M (-1.7%)
|
1.34B
est: 1.36B (-1.2%)
|
1.54B
est: 1.56B (-1.5%)
|
1.67B
est: 1.90B (-12.2%)
|
1.68B
est: 1.95B (-13.9%)
|
2.26B
est: 2.26B (+0.4%)
|
2.75B
est: 2.34B (+17.4%)
|
2.53B
est: 2.70B (-6.3%)
|
3.30B
est: 3.70B (-10.7%)
|
10.81B
est: 7.60B (+42.2%)
|
4.37B
3.83B – 4.82B
-42.5% YoY
|
4.63B
3.76B – 5.76B
+5.8% YoY
|
5.01B
4.22B – 5.89B
+8.2% YoY
|
| EBIT |
614.40M
est: 496.08M (+23.9%)
|
997.78M
est: 853.48M (+16.9%)
|
1.24B
est: 1.16B (+7.1%)
|
1.22B
est: 1.33B (-8.3%)
|
1.33B
est: 1.62B (-17.9%)
|
1.34B
est: 1.67B (-19.7%)
|
1.94B
est: 1.93B (+0.4%)
|
2.38B
est: 2.00B (+18.9%)
|
2.19B
est: 2.31B (-5.0%)
|
2.91B
est: 3.30B (-11.9%)
|
10.29B
est: 6.79B (+51.6%)
|
3.90B
3.42B – 4.30B
-42.5% YoY
|
4.13B
3.36B – 5.14B
+5.8% YoY
|
4.47B
3.77B – 5.26B
+8.2% YoY
|
| Net Income |
526.28M
est: 609.42M (-13.6%)
|
712.56M
est: 708.63M (+0.6%)
|
935.39M
est: 870.17M (+7.5%)
|
1.28B
est: 1.03B (+24.5%)
|
973.72M
est: 1.16B (-16.0%)
|
835.79M
est: 1.33B (-37.1%)
|
1.65B
est: 1.51B (+9.0%)
|
1.92B
est: 1.80B (+6.6%)
|
1.55B
est: 1.98B (-21.7%)
|
2.09B
est: 2.15B (-2.9%)
|
8.26B
est: 9.00B (-8.2%)
|
2.72B
2.17B – 3.35B
-69.7% YoY
|
2.86B
2.28B – 3.52B
+5.2% YoY
|
3.12B
2.48B – 3.83B
+9.0% YoY
|
| SGA |
886.63M
est: 721.10M (+23.0%)
|
1.32B
est: 1.24B (+6.3%)
|
1.65B
est: 1.69B (-2.4%)
|
2.01B
est: 1.94B (+3.6%)
|
2.63B
est: 2.36B (+11.4%)
|
2.47B
est: 2.43B (+1.8%)
|
2.70B
est: 2.80B (-3.8%)
|
2.96B
est: 2.91B (+1.8%)
|
3.49B
est: 3.35B (+4.1%)
|
3.85B
est: 3.51B (+9.7%)
|
4.16B
est: 7.22B (-42.4%)
|
4.15B
3.64B – 4.58B
-42.5% YoY
|
4.40B
3.57B – 5.47B
+5.8% YoY
|
4.76B
4.01B – 5.60B
+8.2% YoY
|
| EPS |
0.23
est: 0.25 (-6.9%)
|
0.28
est: 0.29 (-2.5%)
|
0.37
est: 0.35 (+4.9%)
|
0.46
est: 0.42 (+10.6%)
|
0.38
est: 0.47 (-19.2%)
|
0.33
est: 0.54 (-38.8%)
|
0.65
est: 0.61 (+5.9%)
|
0.78
est: 0.73 (+7.1%)
|
0.63
est: 0.80 (-21.5%)
|
0.86
est: 0.87 (-1.5%)
|
3.43
est: 3.65 (-6.0%)
|
1.10
0.88 – 1.36
-69.7% YoY
|
1.16
0.92 – 1.43
+5.2% YoY
|
1.27
1.01 – 1.56
+9.0% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-19 | A | 4/5 | 4/5 | 5/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-18 | A | 4/5 | 4/5 | 5/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-08 | A+ | 4/5 | 4/5 | 5/5 | 5/5 | 3/5 | 4/5 | 3/5 |
| 2026-05-04 | A+ | 4/5 | 4/5 | 5/5 | 5/5 | 3/5 | 4/5 | 3/5 |
| 2026-04-23 | A | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-22 | A | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Invesco S&P Emerging Markets Momentum ETF EEMO | 0.14% | 35.2K | 0.29% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Jing Lou | Co-Founder, Executive Chairman, Chief Executive Officer & President | 849.1K | — |
| Dongmei Su | Senior Vice President & Executive Director | 219.2K | — |
| Xiang He | Chief Financial Officer | — | male |
| Yanli Liu | General Manager of Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | — | female |
| Yong Xu | General Manager of Shenzhen Sciprogen Bio-pharmaceutical Technology Co., Ltd. | — | male |
| Zhao Xinyi | Executive of IR | — | — |
| An Yu | General Manager of Zhejiang Sunshine Mandi Pharmaceutical Co., Ltd. | — | male |
| Zheng Jin | General Manager of Shenyang Sunshine Pharmaceutical Co., Ltd. | — | male |
| Siu Kuen Lai FCIS | Company Secretary | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for TRSBF
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
